Objective: To study biomarkers of angiogenesis in Parkinson disease (PD), and how these are associated with clinical characteristics, blood-brain barrier (BBB) permeability, and cerebrovascular disease.
Angiogenesis is regulated by a plethora of different proteins, including members of the vascular endothelial growth factor (VEGF) family (e.g., VEGF and its receptors, VEGFR-1 and VEGFR-2, placental growth factor [PlGF]), 5 the angiopoietin (Ang) family (e.g., Ang2), 6 and proinflammatory chemokines (e.g., interleukin [IL]-8). 7 Previous postmortem studies exploring the role of angiogenesis in PD have included few cases. 1, 2 Consequently, there is a need to determine whether biomarkers of angiogenesis are reliably changed in PD. Moreover, the contribution of aberrant angiogenesis to specific aspects of PD symptomatology (such as cognitive or motor dysfunction) has not been investigated. It would be also interesting to establish if changes in angiogenesis biomarkers are associated with overall cerebrovascular pathology. To this end, we measured several biomarkers of angiogenesis in CSF samples from a large cohort of patients with PD with and without dementia and healthy controls. We investigated cross-sectional associations between the measured angiogenesis markers and disease symptoms, blood-brain barrier (BBB) permeability, white matter lesions (WML), and cerebral microbleeds (CMB). Finally, the main findings of the study were replicated in 2 additional cohorts of healthy controls and patients with PD, of which one consisted of neuropathologically confirmed cases.
METHODS Standard protocol approvals, registrations, and patient consents. The Ethics Committee of Lund University approved both studies originating from Lund. Study participants gave informed consent to research. The study was conducted in accordance with the provisions of the Helsinki Declaration.
Study population. Cohort 1. One hundred patients with PD and 38 healthy controls were enrolled in the prospective Swedish BioFinder study (www.biofinder.se) at the Neurology Clinic, Skåne University Hospital, Lund, Sweden. The PD group included 82 patients without dementia (PDND) and 18 patients with dementia (PDD). PD diagnosis was set according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria. 8 PDD was diagnosed according to the Clinical Diagnostic Criteria for Dementia Associated with Parkinson's Disease. 9 Analysis of the data from cohort 1 indicated that to provide 90% power at an a level of 0.05, a total of 100 patients would be required.
Cohort 2. The first validation cohort included 64 healthy controls and 87 patients (25 PDD and 62 dementia with Lewy bodies [DLB] ), all assessed at the Memory Clinic, Skåne University Hospital, Lund, Sweden.
Cohort 3. The second independent validation cohort included 35 healthy controls, 27 PDND patients, and 66 PDD patients, all neuropathologically confirmed cases selected by the Arizona Parkinson's Disease Consortium National Brain and Tissue Resource for Parkinson's Disease and Related Disorders. All participants or their legal representatives signed an Institutional Review Board-approved informed consent form before the time of death. The PDD group included 32 patients without ADrelated histopathology and 34 patients with sufficient load of plaques and tangles to meet criteria for AD diagnosis. The 2 dementia groups were finally merged into one single group of PDD cases because the concurrent AD pathology was found not to have any impact on the parameters under investigation.
Detailed information on all the study cohorts is available in the supplemental data on the Neurology ® Web site at Neurology.org.
CSF sampling and biological assays. In cohort 1 and cohort 2, CSF was collected as described previously. 10 In cohort 3 with neuropathology confirmed cases, postmortem CSF was collected from the lateral ventricles while the brain was still in situ, after removal of the skullcap. VEGF, PlGF, sVEGFR-1, sVEGFR-2, Ang2, and IL-8 were quantified in CSF samples from cohort 1 using multiplex electrochemiluminescence immunoassay (Meso Scale Discovery, Gaithersburg, MD; supplemental data). All the samples were measured in duplicate and the mean of the duplicate was used in the statistical analysis. Detection limits are provided in the supplemental data. The coefficient of variation (CV) was below 20% for all assays. The few samples with CV .20% did not affect the results and were therefore included in the statistical analysis. In the validation cohort, VEGF, PlGF, and sVEGFR-1 were measured using the same methodology as above. For further validation purposes, CSF levels of VEGF were also measured using VEGF V-PLEX kit using other antibodies than the VEGF assay mentioned above (see supplemental data for details).
The albumin ratio was calculated as CSF albumin (mg/L)/ plasma albumin (g/L) and was used as a measure of the BBB function. Albumin and monocyte chemotactic protein-1 (MCP-1) were measured as described previously. 11, 12 Total tau (t-tau; ADx Neurosciences NV, Gent, Belgium), neurofilament light (NFL; Uman Diagnostics, Umeå, Sweden), phospho-tau (p-tau), and b-amyloid (Ab) 42 (Fujirebio Europe, Gent, Belgium) were analyzed using commercially available ELISA kits.
MRI. In cohort 1, 32 controls and 58 patients with PD underwent MRI scans using a 3T Siemens ® system to quantify WMLs and CMB (see supplemental data for details). In addition to CSF concentrations of angiogenesis biomarkers, we also used the VEFG/sVEGFR-1 and PlGF/ sVEGFR-1 ratios when investigating associations with clinical data. The rationale for this is that sVEGFR-1 has direct antagonistic effect on VEFG and PlGF by sequestering the ligands from the membrane receptors. [13] [14] [15] Consequently, high VEGF/ sVEGFR-1 and PlGF/sVEGFR-1 ratios provide an index of the bioactive levels of VEGF and PlGF.
In the control and patient groups, most of the analytes were positively associated with age (p , 0.05). There were also sex differences for VEGF, PlGF, and CSF/plasma albumin ratio (higher levels in men, p , 0.05). Therefore all the subsequent statistical analyses were controlled for age, whereas analyses of VEGF, PlGF, VEGF/sVEGFR-1 ratio, PlGF/sVEGFR-1 ratio, and CSF/plasma albumin ratio were also controlled for sex. In the PD group, status as de novo PD, disease duration, or levodopa equivalent were not associated with any of the measured CSF biomarkers, with the exception of IL-8, which correlated with levodopa equivalent (p , 0.05).
RESULTS Demographic and clinical characteristics of the study participants as well as CSF concentrations of angiogenesis biomarkers for all the cohorts are given in table 1, tables e-1 and e-2. Table 1 Demographic characteristics and CSF levels of angiogenesis biomarkers in healthy controls, patients with PDND, and patients with PDD included in cohort 1 PlGF/sVEGFR-1 ratio (p 5 0.003), and IL-8 (p 5 0.01) were selectively increased in PDD cases compared to controls (figure 1, E and F). Similar results were obtained with the VEGF V-PLEX kit (supplemental data, table e-3). Orthostatic blood pressure might result in transient brain ischemia. 16, 17 PDND patients with a significant drop in diastolic blood pressure when standing had higher levels of VEGF/sVEGFR-1 ratio and PlGF/sVEGFR1 ratio compared with PDND patients without orthostatic diastolic hypotension (p 5 0.029 and p 5 0.014) or with controls (p 5 0.004 and p 5 0.005). The ratios did not differ between PDND patients without orthostatic diastolic hypotension and controls.
Cohort 1: Angiogenesis biomarkers and CSF/plasma albumin ratio. Increased levels of CSF/plasma albumin ratio often reflects increased permeability of the BBB. 18 The CSF/plasma albumin ratio differed between the diagnostic groups (p 5 0.005; table 1). The ratio was higher in PDND patients (p 5 0.001) and PDD patients (p 5 0.027) compared to controls (figure 2A), while no difference was found between PDND patients and PDD patients. In all patients with PD, higher CSF/plasma albumin ratio was associated with higher CSF levels of VEGF (b 5 0.48, p , 0.001; figure 2B ) and PlGF We observed similar associations when only including PDND patients (data not shown). In the control group, we did not find any significant associations between CSF/plasma albumin ratio and any of the angiogenesis variables or ratios (all p . 0.16). including PDND patients, we found similar results (data not shown). In the control group, we did not find any significant associations between total ARWMC score and any of the angiogenesis variables or ratios (all p . 0.14).
Patients with PD with signs of CMB (n 5 13) had higher VEGF (p 5 0.051) and PlGF (p 5 0.020) levels than those who did not have CMB (n 5 37).
Cohort 1: Angiogenesis biomarkers and markers of neurodegeneration and neuroinflammation. NFL is a marker of axonal neurodegeneration. 19 In patients with PD, higher levels of NFL in CSF are associated with more severe disease. 20 Positive associations were found between CSF NFL levels and VEGF CSF t-tau levels are considered to reflect cortical neurodegeneration, 18 and the CSF tau levels did not correlate with PlGF or VEGF. Further, there were no correlations between PlGF and VEGF and the Alzheimer-specific biomarkers CSF p-tau or Ab42.
To study possible associations of angiogenesis biomarkers with neuroinflammation, we measured the CSF levels of MCP-1, which is a chemoattractant expressed by microglia and astrocytes in the brain 21 that can be reliably measured in CSF. 22 MCP-1 was associated with VEGF in the patients with PD (b 5 0.25, p 5 0.027) but not in the controls.
The associations with markers of neurodegeneration and neuroinflammation were similar when only including PDND patients (data not shown).
Cohort 2: Validation study. In this cohort of controls and PDD/DLB patients, we analyzed CSF levels of VEGF, PlGF, and sVEGFR1. The patient group displayed higher mean levels of PlGF (p 5 0.002), VEGF/sVEGFR-1 ratio (p , 0.001), and PlGF/ sVEGFR-1 ratio (p , 0.001) compared to the healthy controls (figure 3, A-C). In this cohort of patients we also confirmed the association of CSF/ plasma albumin ratio with VEGF (b 5 0.48, p , 0.001) and PlGF (b 5 0.42, p 5 0.002). Using VEGF V-PLEX kit, we found that VEGF levels were elevated in the PDD/DLB patients compared to the healthy controls (supplemental data).
Cohort 3: Validation study. In this cohort of neuropathologically confirmed cases, we measured VEGF, PlGF, and sVEGFR-1 in postmortem ventricular CSF samples from PDND and PDD participants as well as healthy controls. In agreement with our previous findings, both the PDND and PDD groups showed elevated levels of VEGF (p 5 0.016 and p 5 0.034) and PlGF (p 5 0.037 and p 5 0.002) compared to the controls ( figure 3, D and E) . We did not find any difference in these analytes between the PDND and PDD groups. In all patients with PD, the total burden of WMLs was associated with higher CSF levels of VEGF (b 5 0.24, p 5 0.016), confirming our previous finding when comparing WMLs according to MRI and angiogenesis biomarkers in CSF. When only including the Figure 3 CSF levels of angiogenesis biomarkers (cohorts 2 and 3)
(A-C) Placental growth factor (PlGF), vascular endothelial growth factor (VEGF)/sVEGFR-1 ratio, and PlGF/sVEGFR-1 ratio are higher in patients with Parkinson disease with dementia (PDD)/patients with dementia with Lewy bodies (DLB) than in controls in cohort 2. (D, E) VEGF and PlGF levels are elevated in patients with Parkinson disease without dementia (PDND) and patients with PDD compared to controls in cohort 3 with neuropathologically confirmed diagnosis. Angiogenesis biomarkers were skewed and therefore ln-transformed before statistical analyses; p values are from analysis of covariance adjusting for age and sex as described in the Methods; data are presented as mean 6 95% confidence interval.
PDND patients, we found similar results (data not shown). There were no associations between CSF levels of either VEGF or PlGF and amyloid plaque density (quantified according to the Consortium to Establish a Registry for Alzheimer's Disease templates) or Braak tangle scores in patients with PD, suggesting that changes in angiogenic factors are not related to AD amyloid or tau pathology. These findings confirm the results obtained in cohort 1 using CSF AD biomarkers.
DISCUSSION Using a well-characterized clinical sample, this study demonstrates that CSF levels of VEGF, PlGF, and sVEGFR-2 are high, while levels of Ang2 are low, in PDND and PDD patients compared to non-PD controls. We corroborate our findings of elevated CSF levels of VEGF and PlGF in 2 additional cohorts of patients with PD with and without dementia.
The increased CSF levels of angiogenesis factors in PD are in keeping with postmortem studies demonstrating high levels of VEGF and elevated numbers of endothelial cell nuclei and vessels in the SNpc of patients with PD, as well as primates with parkinsonian lesions. [1] [2] [3] 23 Previous reports have also suggested that PD might be accompanied by BBB dysfunction. 24, 25 In agreement with these reports, we found higher CSF/plasma albumin ratio in patients with PD compared to controls. Furthermore, we observed robust positive correlations between angiogenic factors and CSF/plasma albumin ratio, which is interesting considering that VEGF is a potent trigger of vascular leakage and BBB dysfunction. 26, 27 In other neurodegenerative diseases, mild but chronic increases in BBB permeability are known to contribute to neuronal dysfunction and neurodegeneration. 28 Of relevance to PD, intranigral administration of VEGF induces BBB breakdown and loss of dopaminergic neurons. 29 On the contrary, the angiogenic factor Ang2 decreases BBB leakage. 30 Thus, increased levels of VEGF and PlGF, and decreased levels of Ang2, may concur to produce BBB dysfunction and neuronal toxicity in the affected brain regions. Accordingly, we found strong correlations between the CSF levels of NFL (a marker of axonal degeneration) and angiogenesis biomarkers in patients with PD.
BBB abnormalities are likely to be associated with structurally altered and leaky small vessels that may result in CMB. 31 High serum VEGF and increased vascular permeability have been previously linked to CMB in acute ischemic stroke. 32 Here we show that patients with PD with CMB have elevated CSF levels of VEGF and PlGF. These findings raise the possibility that angiogenic factors are involved in the pathogenesis of CMB, in addition to BBB dysfunction, in PD.
The mechanisms behind the observed alterations in angiogenesis biomarkers in PD are yet to be elucidated. In the present study, we found that patients with PD with orthostatic diastolic hypotension have increased levels of VEGF and PlGF compared to patients without orthostatic diastolic hypotension. Orthostatic hypotension might result in recurrent episodes of transient cerebral hypoperfusion and hypoxia in cases with suboptimal autoregulation of cerebral blood flow as for example in PD. 33, 34 Hypoxia-induced VEGF signaling is one of the main molecular pathways triggering angiogenic responses. 35 Hypoperfusion and hypoxia have been also proposed as a potential mechanism underlying previously observed association between orthostatic hypotension and WMLs. 16, 36 We found that increased levels of VEGF and PlGF in the CSF of patients with PD were related to more pronounced WMLs. Thus, elevated levels of angiogenesis biomarkers in patients with PD in our study may partly depend on the hypoxic environment associated with orthostatic hypotension and WMLs. WMLs have been linked to gait abnormalities and postural instability in large cohorts of healthy elderly individuals as well as patients with PD. 37 Accordingly, in our PD cohorts elevated levels of VEGF and PlGF correlated with poor performance on the Tandem Gait Test. These findings suggest that WMLs and increased angiogenesis underpin, at least to some extent, the treatment-resistant symptoms that develop during the course of PD, such as postural instability and gait difficulties.
In our study, VEGF positively correlated with MCP-1, a proinflammatory chemokine expressed by astrocytes and microglia. 21 Interestingly, one previous study reported a greater number of activated microglia together with signs of angiogenesis in the SNpc of parkinsonian brain. 4 Others have shown that VEGF production can be triggered in astrocytes by proinflammatory cytokines. 38, 39 Collectively, these data suggest a possible link between neuroinflammation and angiogenesis in PD.
One potential limitation of the current study is the cross-sectional study design, thus causality may not be inferred. Another limitation is that it is not possible to obtain any regional or structural information using CSF. On the other hand, analysis of material, such as CSF, from living individuals with PD has some advantages over postmortem investigations. Relatively large series of patients can be studied, findings can easily be related to current symptomatology and imaging data in the same participants, and the results are not biased by deathrelated events, such as hypoxia. The proportion of individuals with major somatic comorbidities or using of anti-inflammatory medications did not significantly differ across groups, thus these factors are unlikely to have confounded our findings. A strength of the present study was the multimodal characterization of the original prospective cohort with clinical assessments, brain imaging, and different CSF biomarkers. Further, the main results obtained in the original cohort were validated in 2 independent cohorts, of which one consisted of neuropathologically confirmed cases. Finally, different ELISAs were used to measure VEGF in CSF, resulting in similar differences between diagnostic groups.
In the present study, we established that angiogenic factors are upregulated in the CSF in PD. The angiogenic activation was associated with gait difficulties, BBB dysfunction, WMLs, CBM, neuroinflammation, and axonal degeneration in patients but not in the control group, suggesting that these interactions are specific for PD. Our results warrant further mechanistic studies on the role of angiogenesis and cerebrovascular dysfunction in the development of some symptoms that respond poorly to dopamine replacement therapy in PD. These studies may have an important impact on the design of new personalized therapeutic approaches.
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